Skip to Main Content

Practice Guidelines: Adults

Below you will find links in which you can access the Clinical Practice Guidelines set by the American Psychiatric Association.

 

ALERT: SIBUTRAMINE – Abbott Laboratories and the U.S. Food and Drug Administration (FDA) notified healthcare professionals and patients about the voluntary withdrawal of Meridia (sibutramine), an obesity drug, from the U.S. market because of clinical trial data indicating an increased risk of heart attack and stroke. Physicians are advised to stop prescribing Meridia to their patients, including for binge eating disorder, and patients should stop taking this medication.

*NOTICE – This guideline is more than 5 years old and has not yet been updated to ensure that it reflects current knowledge and practice. In accordance with national standards, including those of the Agency for Healthcare Research and Quality’s National Guideline Clearinghouse, this guideline can no longer be assumed to be current.